Skip to main content
. 2023 Jan 9;9:1089219. doi: 10.3389/fmed.2022.1089219

TABLE 3.

Outcome variables excluding TBI with abbreviated injury scale of 3 or more points.

Using of antiplatelet drugs Using of anticoagulant
Outcome N Overall, N = 519 No, N = 483a Yes, N = 36a No, N = 504a Yes, N = 15a
Mortality within 24 h 518
Died 13 (2.5%) 13 (2.7%) 0 (0.0%) 13 (2.6%) 0 (0.0%)
Survived 505 (97.5%) 469 (97.3%) 36 (100.0%) 490 (97.4%) 15 (100.0%)
28 day-mortality 508
Died 21 (4.1%) 19 (4.0%) 2 (5.6%) 21 (4.3%) 0 (0.0%)
Survived 487 (95.9%) 453 (96.0%) 34 (94.4%) 472 (95.7%) 15 (100.0%)
Mortality at hospital discharge 517
Died 25 (4.8%) 23 (4.8%) 2 (5.6%) 25 (5.0%) 0 (0.0%)
Survived 492 (95.2%) 458 (95.2%) 34 (94.4%) 477 (95.0%) 15 (100.0%)
Surgery for hemostasis 517 82 (15.9%) 79 (16.4%) 3 (8.3%) 80 (15.9%) 2 (13.3%)
TAE 518 85 (16.4%) 79 (16.4%) 6 (16.7%) 85 (16.9%) 0 (0.0%)
RBC transfusion 510 0.0 (0.0, 560.0) 0.0 (0.0, 560.0) 0.0 (0.0, 420.0) 0.0 (0.0, 560.0) 0.0 (0.0, 0.0)
FFP transfusion 510 0 (0.0, 480.0) 0.0 (0.0, 720.0) 0.0 (0.0, 360.0) 0.0 (0.0, 600.0) 0.0 (0.0, 0.0)
PC transfusion 508 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)

aStatistical data are presented as the median (interquartile range) or n (%). TAE, transcatheter arterial embolization; RBC, red blood cell; FFP, fresh frozen plasma; PC, platelet concentrate.